Advances in pharmacotherapy for opioid-induced constipation – a systematic review

Bibliography

• Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72(14):1847-65
   PubMed Web of Science ®Google Scholar
• Poulsen JL, Brock C, Olesen AE, et al. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. CEG 2014;345-58
   Google Scholar
• Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 2009;373(9670):1198-206
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-8S
   PubMed Web of Science ®Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and european patient survey (PROBE 1). Pain Med 2009;10(1):35-42
   PubMed Web of Science ®Google Scholar
• Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61(7):1181-7
   PubMed Web of Science ®Google Scholar
• Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93(3):247-57
   PubMed Web of Science ®Google Scholar
• Coyne K, LoCasale R, Datto C, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. CEOR 2014;23(6):269-81
   Google Scholar
• Hjalte F, Berggren A, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40(5):696-703
   PubMed Web of Science ®Google Scholar
• Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2014;49(1):9-16
   Web of Science ®Google Scholar
• Joswick T, Mareya SM, Lichtlen P, et al. Time to onset of lubiprostone treatment effect in chronic non-cancer pain patients with opioid-induced constipation: data from two phase 3, randomized, double-blind, placebo-controlled trials. Gastroenterology 2013;144(5 Suppl 1):540
   Google Scholar
• Mareya SM, Lichtlen P, Woldegeorgis F, et al. Lubiprostone improves complete spontaneous bowel movement frequency in chronic non-cancer pain patients with opioid-induced constipation. Gastroenterology 2013;144(5 Suppl 1):539-40
   Web of Science ®Google Scholar
• Ishihara M, Iihara H, Okayasu S, et al. Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients. Support Care Cancer 2010;18(12):1531-8
   PubMed Web of Science ®Google Scholar
• Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130(5):1377-90
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
   PubMed Web of Science ®Google Scholar
• Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract 2011;65(4):472-8
   PubMed Web of Science ®Google Scholar
• Iyer SS, Randazzo BP, Tzanis EL, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health 2011;14(1):177-83
   PubMed Web of Science ®Google Scholar
• Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137(2):428-40
   PubMed Web of Science ®Google Scholar
• Wirz S, Nadstawek J, Elsen C, et al. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care 2012;21(1):131-40
   PubMed Web of Science ®Google Scholar
• Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):175-84
   PubMed Web of Science ®Google Scholar
• Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):185-93
   PubMed Web of Science ®Google Scholar
• Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009;13(7):737-43
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Thomas J, Moehl BM, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35(5):458-68
   PubMed Web of Science ®Google Scholar
• Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Cancer 2008;16(9):999-1009
   PubMed Web of Science ®Google Scholar
• Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl 2014;2(1):31-7
   PubMedGoogle Scholar
• Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract 2014;2014(1):1-6
   Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105-20
   PubMed Web of Science ®Google Scholar
• Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004;361(1-3):192-5
   PubMed Web of Science ®Google Scholar
• Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998;6(4):356-64
   PubMed Web of Science ®Google Scholar
• Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55(10):2912-21
   PubMed Web of Science ®Google Scholar
• Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370(25):2387-96
   PubMed Web of Science ®Google Scholar
• Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013;154(9):1542-50
   PubMed Web of Science ®Google Scholar
• Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23(1):48-53
   PubMed Web of Science ®Google Scholar
• Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction–a 21-day treatment-randomized clinical trial. J Pain 2005;6(3):184-92
   PubMed Web of Science ®Google Scholar
• Viscusi E, Barrett A, Paterson C, et al. (451) Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis. J Pain 2014;15(4):S88
   Web of Science ®Google Scholar
• Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12(5):554-62
   PubMed Web of Science ®Google Scholar
• Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):175-84
   PubMed Web of Science ®Google Scholar
• Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):185-93
   PubMed Web of Science ®Google Scholar
• Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137(2):428-40
   PubMed Web of Science ®Google Scholar
• Jamal MM, Mareya SM, Woldegeorgis F, et al. Lubiprostone significantly improves treatment response in non-methadone opioid-nduced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3 randomized double-blind placebo-controlled clinical trial. Gastroenterology 2012;142(5):144-5
   Web of Science ®Google Scholar
• Cryer BL, Katz S, Vallejo R, et al. A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology 2010;138(Suppl 1):S129
   Google Scholar
• Loewenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10(4):531-43
   PubMed Web of Science ®Google Scholar
• Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011(1):CD003448
   PubMed Web of Science ®Google Scholar
• Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone. Drugs 2013;73(12):1297-306
   PubMed Web of Science ®Google Scholar
• Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol 2013;108(10):1566-74
   PubMed Web of Science ®Google Scholar
• Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med 2012;7(2):67-72
   PubMed Web of Science ®Google Scholar
• Rauck RL, Peppin J, Israel R, et al. Oral methylnaltrexone for the treatment of opioid-induced constipation in patients with noncancer pain. Gastroenterology 2012;142(Suppl 1):160
   Google Scholar
• Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7(1):39-46
   PubMedGoogle Scholar
• Portenoy RK, Thomas J, Moehl BM, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35(5):458-68
   PubMed Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358(22):2332-43
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13(1):56-64
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24(12):3503-12
   PubMed Web of Science ®Google Scholar
• Tack J, Corsetti M. Naloxegol for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol 2014;8(8):855-61
   PubMed Web of Science ®Google Scholar
• Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther 2014;40(7):771-9
   PubMed Web of Science ®Google Scholar
• Cryer B, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15(11):1825-34
   PubMed Web of Science ®Google Scholar
• Singla NK, Techner LM, Gabriel K, et al. CB-5945 0.25 mg Twice daily is associated with significantly increased spontaneous bowel movement and greater proportion of responders compared with placebo in patients on chronic opioid therapy for noncancer pain (45CL242; NCT01207427). Gastroenterology 2012;143(3):26-7
   PubMed Web of Science ®Google Scholar
• Lichtlen P, Joswick T, Woldegeorgis F, et al. Lubiprostone is well tolerated in chronic non-cancer pain patients with opioid-induced constipation in three phase 3, randomized, double-blind, placebo-controlled trials. Gastroenterology 2013;144(5 Suppl 1):916
   Google Scholar
• Mackey AC, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40(1):e1
   PubMedGoogle Scholar
• Bader S, Dürk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol 2013;7(1):13-26
   PubMed Web of Science ®Google Scholar
• Entereg (Alvimopan) Capsules. Safety labeling changes approved by FDA center for drug evaluation and research (CDER). U.S FDA. 2013. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm194328.htm [Last accessed 3 November 2014]
   Google Scholar
• Levels of evidence. Oxford centre for evidence-based medicine 2009. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ [Last accessed 28 October 2014]
   Google Scholar
• Higgins JPT, Altman DG. editors. Assessing risk of bias in included studies. John Wiley & Sons; Sussex: 2008
   Google Scholar
• Meerpohl JJ, Langer G, Perleth M, et al. GRADE-Leitlinien: 3. Bewertung der qualität der evidenz (vertrauen in die effektschätzer). zeitschrift für evidenz, fortbildung und qualität im gesundheitswesen. 2012;106(6):449-56
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12
   PubMed Web of Science ®Google Scholar